Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
At each centre, approximately 12-15 Pulmonary Arterial Hypertension (PAH) consecutive patients who have received Thelin and who meet all other study entry criteria.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Idiopathic PAH, or PAH secondary to connective tissue disease
Receipt of Thelin for treatment of PAH
6 months of follow-up (except in the event of death) subsequent to initial receipt of Thelin
Minimum of one clinic visit documented in the medical record during the 6-month period subsequent to initial receipt of Thelin
You may not be if
Participation in any investigational study of Thelin or any other medication for the treatment of PAH during the period beginning 6 months prior to initial receipt of Thelin and ending 6 months subsequent to such receipt
Receipt of Thelin prior to January 11, 2005 (i.e., the date following the last day on which patients could be enrolled in double-blind treatment in STRIDE-1, STRIDE-2, and/or STRIDE-6); or
Known contraindications to Thelin therapy (i.e., known hypersensitivity to sitaxsentan or any of its excipients; mild-to-severe hepatic impairment \[Child-Pugh Class A-C\]; elevated aminotransferases prior to initiation of treatment, defined as aspartate aminotransferase \[AST\] and/or alanine aminotransferase \[ALT\] \>3 times upper limit of normal \[ULN\]; concomitant use of cyclosporin A; lactation)
